NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.
The partners will develop theranostic tools for the screening and monitoring of colorectal cancer as part of the deal, which aims to evaluate the expression and predictive role of miRNA in treatment response to radio- and chemotherapies for the disease. Theradiag will identify biomarkers that may be developed into theranostic assays, the partners said.
Financial and other terms of the deal were not disclosed.
Theradiag also announced that it opened a new laboratory dedicated to applied research for the development of miRNA-based assays within the Cap Alpha incubator in Montpellier.
Theradiag bought miRNA-based technology firm Prestizia a year ago.